• Norovirus Hijacks NINJ1 for Selective NS1 Protein Secretion

  2026-05-01

  Song et al. reveal that murine norovirus co-opts the host protein NINJ1 to selectively secrete its NS1 protein through a caspase-3-dependent, unconventional pathway. This finding redefines our understanding of regulated plasma membrane rupture and viral manipulation of host cell death machinery, with implications for studying secretion and immune evasion in viral infections.

• Precision Use of BPN-19186 in sEH-Nrf2 Pathway Assays: A Res

  2026-05-01

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) enables advanced, reproducible sEH-Nrf2 signaling research. Discover protocol guidance, mechanistic insights, and expert analysis for optimizing biochemical and disease-model assays.

• SARS-CoV-2 N Protein Suppresses GADD34-Mediated Innate Immun

  2026-04-30

  This study uncovers how the SARS-CoV-2 nucleocapsid protein disrupts innate immune signaling by sequestering GADD34 mRNA into atypical stress granule-like foci, ultimately impairing interferon responses. The mechanistic insights offer new directions for antiviral research and targeted modulation of cellular stress pathways.

• Dihydrotestosterone (DHT): Precision Tools for AR Signaling

  2026-04-30

  Dihydrotestosterone (DHT) is redefining research on androgen receptor signaling, EGFR/ERBB2 pathways, and therapeutic resistance mechanisms in cancer and neuromuscular models. Leveraging APExBIO's high-purity DHT, advanced workflows enable reproducible modulation of signaling cascades and empower troubleshooting in complex in vitro and in vivo settings.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-04-29

  This dissertation by Hannah R. Schwartz rigorously dissects how distinct in vitro metrics—relative viability and fractional viability—capture different facets of anti-cancer drug responses, challenging the practice of using them interchangeably. By clarifying how drugs variably affect proliferation and cell death, the work delivers a practical framework for interpreting drug efficacy in preclinical cancer models.

• AP20187 in Conditional Gene Therapy: Precision by Design

  2026-04-29

  Explore how AP20187, a leading chemical inducer of dimerization, enables next-generation control in conditional gene therapy. This article uniquely integrates mechanistic insight with advanced assay design and practical guidance for translational research.

• UGDH Phosphorylation Drives Glycosaminoglycan Synthesis and

  2026-04-28

  This study reveals that phosphorylation of UDP-glucose dehydrogenase (UGDH) at serine 316 by AGC kinases reprograms glycosaminoglycan biosynthesis in prostate cancer cells, promoting motility, spheroid growth, and resistance to enzalutamide. These findings highlight a novel metabolic mechanism of therapeutic resistance with direct implications for castration-resistant prostate cancer research.

• Ganetespib (STA-9090) in Cancer Research: Applied Protocols

  2026-04-28

  Ganetespib (STA-9090) stands out for its rapid, high-affinity Hsp90 inhibition and broad antitumor efficacy in both cellular and animal models. This guide details evidence-backed workflows, advanced troubleshooting, and strategic opportunities to optimize experimental results with this triazolone-based small molecule—empowering translational oncology research.

• Imatinib Hydrochloride: Advanced Tyrosine Kinase Inhibitor W

  2026-04-27

  Imatinib hydrochloride (STI571 hydrochloride) offers multi-target kinase inhibition for robust cancer research, streamlining workflows in CML and GIST models. This guide translates recent dual-action mechanistic insights into protocol-level advantages, troubleshooting, and assay optimization.

• GPR30 in Spinal CCK+ Neurons: A Key Modulator of Neuropathic

  2026-04-27

  This study establishes spinal GPR30 (GPER) expression in cholecystokinin-positive (CCK+) neurons as a critical driver of neuropathic pain. By combining molecular, electrophysiological, and chemogenetic approaches, the research provides mechanistic insight into how GPR30-mediated signaling shapes pain circuits and highlights new intervention targets.

• Quizartinib (AC220): Mechanisms & Strategic Leverage in AML

  2026-04-26

  This article delivers mechanistic clarity and strategic guidance for translational researchers leveraging Quizartinib (AC220) in acute myeloid leukemia (AML) research. Anchored by precision evidence, it bridges foundational FLT3 biology, robust experimental validation, and the evolving clinical landscape—highlighting the product's unique value, referencing recent cross-domain insights on programmed cell death, and escalating the discussion beyond standard product resources.

• Strategic Wnt Pathway Inhibition: Translational Leverage wit

  2026-04-25

  This thought-leadership article provides translational researchers in cancer and stem cell biology with a mechanistic and strategic framework for leveraging PNU 74654, a high-purity Wnt signaling pathway inhibitor from APExBIO. Integrating recent evidence on the WNT5a/GSK3/β-catenin axis in muscle progenitor adipogenesis, we detail practical assay guidance, dissect the competitive landscape, and highlight how precise Wnt/β-catenin inhibition can reshape experimental paradigms and translational impact. This article bridges biological rationale, workflow validation, and future outlook in a single, evidence-led narrative.

• Prevotella copri Depletion of IPA Drives Breast Cancer via A

  2026-04-24

  This study reveals that Prevotella copri, enriched in the gut microbiota of breast cancer patients, depletes host indole-3-pyruvic acid (IPA), impairing an intrinsic anti-tumor pathway via UHRF1-mediated inactivation of AMPK. The findings establish a direct mechanistic link between microbial tryptophan metabolism and breast cancer progression.

• RNA Pol II Inhibition Triggers Apoptosis via Active Signalin

  2026-04-24

  Harper et al. (2025) reveal that inhibition of RNA polymerase II induces apoptosis not through passive mRNA decay but via an active, regulated signaling cascade initiated by the loss of hypophosphorylated RNA Pol IIA. These findings redefine our understanding of transcription-linked cell death, with significant implications for cancer therapy research and apoptosis-targeting compounds.

• Rucaparib (AG-014699): Precision PARP1 Inhibition in DNA Rep

  2026-04-23

  This thought-leadership article explores Rucaparib (AG-014699) as a strategic tool for translational researchers investigating DNA damage response, with mechanistic insights into apoptosis signaling beyond transcriptional loss. The article connects recent discoveries on regulated cell death, examines workflow optimization, and highlights APExBIO’s Rucaparib as a benchmark for robust and reproducible cancer biology research.

16250 records 1/1084 page Next 12345 下5页 Last page